Skinvisible Financials

Skinvisible (SKVI) reported $20K in total revenue for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Skinvisible (SKVI) revenue grew by 0% year-over-year, from $20K to $20K in fiscal year 2025.

Skinvisible (SKVI) had EBITDA of -$476K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Skinvisible (SKVI) had a gross margin of 100.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Skinvisible (SKVI) had an operating margin of -2481.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Skinvisible (SKVI) generated -$42K in free cash flow during fiscal year 2025. This represents a 46.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Skinvisible (SKVI) generated -$38K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Skinvisible (SKVI) had $128K in total assets as of fiscal year 2025, including both current and long-term assets.

Skinvisible (SKVI) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Skinvisible (SKVI) had 5M shares outstanding as of fiscal year 2025.

Skinvisible (SKVI) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Based on fiscal year 2025 data, Skinvisible (SKVI) had $3K in cash against an annual operating cash burn of $38K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Skinvisible (SKVI) has negative shareholder equity of -$10.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Skinvisible (SKVI) has an Altman Z-Score of -509.64, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Skinvisible (SKVI) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Skinvisible (SKVI) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.